Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis

@article{Joy2010EffectsOU,
  title={Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis},
  author={Melanie S. Joy and Tammy Boyette and Yichun Hu and Jinzhao Wang and Mary K. La and Susan Leininger Hogan and Paul W Stewart and Ronald J. Falk and Mary Anne Dooley and Philip D. Coleridge Smith},
  journal={European Journal of Clinical Pharmacology},
  year={2010},
  volume={66},
  pages={1119-1130}
}
The role of pharmacogenomics, clinical and demographic parameters in pharmacokinetic predictions was evaluated in patients receiving mycophenolic acid (MPA). A cohort study design of patients with glomerulonephritis secondary to lupus nephritis and anti-neutrophil cytoplasmic antibody (ANCA) vasculitis was employed. Forty-six patients with lupus nephritis and ANCA vasculitis who were receiving MPA were recruited from the nephrology clinic. The study assessed the relative single and combined… CONTINUE READING